Primary duodenal follicular lymphoma: 6-years complete remission after combined radio-immunotherapy
| Journal | Volume 74 - 2011 |
| Issue | Fasc.2 - Case reports |
| Author(s) | Pierfrancesco Franco, Andrea Riccardo Filippi, Patrizia Ciammella, Angela Botticella, Agnieszka Namysl-Kaletka, Alberto De Crescenzo, Corrado Tarella, Umberto Ricardi |
| Full article |
 VIEW FREE PDF |
| (1) Department of Medical and Surgical Sciences, Radiation Oncology Unit, University of TorinO. Ospedale S. Giovanni Battista, Turin, Italy; (2) Department of Radio- therapy, Center of Oncology, Maria-Sklodowska-Curie Memorial Institute, Gliwice, Poland; (3) Hematology and Cell Therapies Unit, University of TorinO. Ospedale Umberto I, Turin, Italy. |
|
Primary gastrointestinal lymphoma (PGL) is known to account for 40% of all extranodal non-Hodgkin's lymphomas (NHLs) and between 4% to 12% of all NHLs. The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved. Duodenal localizations have always been thought to be rare, but are presently growing in incidence. We herein report on a case of Stage IV primary duodenal FCL, located to the second por- tion of the duodenum with concomitant minimal bone marrow involvement. The patient was frontline approached with a conser- vative combined modality treatment consisting of 4 weekly infu- sions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duode- nal portion. Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity. (Acta gastroenterol. belg., 2011, 74, 337-342). |
|
© Acta Gastro-Enterologica Belgica. PMID 21861321 |
